Drug Database
MV

MV-130 (Bactek / MV130)

✓ Approved

Inmunotek · Cell-based Therapies · Cell-based Therapies

What is MV-130?

MV-130 is a cell-based therapies developed by Inmunotek. It is approved for therapeutic indications via oral (po) or sublingual (sl)/oral transmucosal.

Drug Profile

Brand NamesBactek, MV130
CompanyInmunotek
Drug ClassCell-based Therapies, Vaccine
RouteOral (PO), Sublingual (SL)/Oral Transmucosal
StatusApproved
Sources: ClinicalTrials.gov, Inmunotek

Therapeutic Indications

MV-130 is developed for 11 unique indications across 4 therapeutic areas.

Therapeutic AreaConditionPhase
Infections and infestationsViral upper respiratory tract infection✓ Approved
Infections and infestationsLower respiratory tract infectionPhase III
Infections and infestationsOtitis mediaPhase II
Infections and infestationsPneumoniaPhase II
Infections and infestationsSinusitisPhase II

+6 more indications available with a free account

Sign up free to view all indications →

Related Research Articles

PubMedFood chemistry: X2026-09-20

Structural optimization and freeze-thaw stabilization of carnauba wax and beta-sitosterol bigels via peanut protein and sodium alginate complexation.

Hu Chun C, Li Chunyu C, Zhang Weinong W, He Junbo J et al.

This study investigated the influence of peanut protein/sodium alginate (PP/SA) complex and oleogel-to-hydrogel ratio on the structure, mechanical properties and stability of carnauba wax/β-sitosterol-based bigels. The results indicated adding SA increased PP mean particle size from 88.1 to 395.2 and 729.6 nm, and absolute zeta-potential from 38.5 to 53.0 and 60.5 mV, and improved its surface hydrophobicity. Additionally, at 40% and 50% oleogel, SA addition was shown to improve the performance of PP bigels in water holding capacity, elastic modulus (G'), viscous modulus (G″), textural properties (hardness, springiness, chewiness and gumminess), as well as physical and freeze-thaw stability. Notably, the bigels with 50% oleogel exhibited the most compact structure and optimal functional properties. However, at 60% oleogel, the PP bigels declined in texture parameters, rheological properties and stability, making the positive effects of SA negligible. These findings provide a theoretical foundation for utilizing PP/SA bigels as potential spreadable sauce substitutes.

PMID 42763530
Read full article →
PubMedInternational journal of nanomedicine2026-09-20

Biotinylated ε-Polylysine-Cyclodextrin-Coated Mesoporous Silica Nanoparticles for Targeted pH-Responsive Baicalin Delivery.

Liao Rongqiang R, Ruan Yi Y, Zhang Ke K, Liu Maoxia M

Baicalin (BAI) is a natural flavonoid with antitumor potential, but its poor water solubility and low bioavailability limit clinical use. Mesoporous silica nanoparticles are promising drug carriers due to their large surface area and tunable pore structure, yet premature drug leakage remains a key challenge. A multifunctional nanoplatform, designated as BPCD@BAI@BMSN, was constructed to enable efficient baicalin loading, pH-responsive gated release, and biotin-mediated active tumor targeting. A novel biotin-ε-polylysine-cyclodextrin (BPCD) conjugate was synthesized via EDCI/NHS coupling and characterized by NMR and GPC. Hollow mesoporous silica nanoparticles (BMSN) were prepared by the Stöber method, surface-modified with benzothiazole. The BPCD conjugate was coated onto the nanoparticle surface via cyclodextrin-benzothiazole host-guest self-assembly. The resulting nanoparticles were characterized by TEM, DLS, zeta potential, FTIR, and TGA. Drug loading, pH-responsive release, cytotoxicity against SMMC-7721 cells, cellular uptake evaluated by confocal microscopy and flow cytometry, and in vivo antitumor efficacy in nude mice were systematically evaluated. BPCD@BAI@BMSN exhibited near-spherical morphology with a particle size of approximately 200 nm, a positive zeta potential of +10 mV, a drug loading of 19.85%, and an encapsulation efficiency of 89.6%. Cumulative baicalin release reached approximately 62% at pH 5.5, whereas only about 6% was released at pH 7.4, confirming acid-triggered gated release. The blank carrier showed no significant cytotoxicity with cell viability above 95%, while drug-loaded nanoparticles exhibited enhanced cytotoxicity at pH 6.8. Biotin-functionalized nanoparticles demonstrated significantly higher cellular uptake and tumor accumulation compared to non-targeted controls. In vivo, BPCD@BAI@BMSN achieved a tumor growth inhibition rate of 72.5% compared to the control group, with no obvious toxicity to major organs observed during the 21-day treatment period. BPCD@BAI@BMSN integrates high drug loading, pH-responsive supramolecular gating, and active tumor targeting into a single nanoplatform, offering a promising strategy for baicalin delivery with enhanced antitumor efficacy and favorable short-term biosafety.

PMID 42763689
Read full article →
PubMedThe Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology2026-09-20

Favorable maternal and neonatal outcomes in probable Eisenmenger physiology with suspected DORV: a case report and literature review.

Mohamed Mohamed Mukhtar MM, Sutaşır Mehmet Necmeddin MN, Ali Khadija Yusuf KY, Dahir Osman Farah OF et al.

Pregnancy in Eisenmenger syndrome is associated with very high maternal and fetal risk. Complex congenital anatomy further complicates diagnosis and peripartum management, particularly where advanced imaging and pulmonary hypertension therapies are limited. Published evidence specifically addressing pregnancy with uncorrected DORV and Eisenmenger physiology remains sparse. A 25-year-old primigravida at 34 weeks' gestation presented with progressive dyspnoea and generalized oedema. The available record documented a heart rate of 130 beats/min, respiratory rate of 25 breaths/min, oxygen saturation of 80% despite face-mask oxygen, a loud second heart sound, and a systolic murmur. Echocardiography showed large ventricular and atrial septal defects with colour Doppler flow, severe tricuspid regurgitation, and an estimated systolic pulmonary artery pressure of 85 mmHg. In the setting of marked hypoxaemia, these findings supported probable Eisenmenger physiology, although shunt direction and pulmonary vascular resistance were not documented. The aorta appeared to arise predominantly from the right ventricle, supporting suspected DORV, but the origin of both great arteries, VSD-great-artery relationship, and DORV subtype could not be defined. Following cardiology and obstetric assessment, labour was induced and vaginal delivery occurred four hours later. The liveborn neonate weighed 2.7 kg, had an initial Apgar score of 5, and was admitted to neonatal intensive care for stabilisation and monitoring. Postpartum haemoglobin fell to 7 g/dL and two units of packed red cells were transfused. The mother was monitored in intensive care for three days, transferred to cardiology on day 6, and discharged in stable condition on day 7. This report documents maternal survival through induced vaginal delivery and the first postpartum week, with a live birth, despite late recognition of probable Eisenmenger physiology and suspected complex congenital heart disease. The report does not establish the safety of vaginal delivery in Eisenmenger syndrome, and incomplete haemodynamic, anatomical, anaesthetic, and neonatal data limit causal interpretation.

PMID 42763816
Read full article →
PubMedMedicine2026-09-19

Efficacy of celecoxib and methotrexate-vinblastine regimen in desmoid-type fibromatosis: A retrospective cohort study.

Kawano Masanori M, Kubota Yuta Y, Itonaga Ichiro I, Kaku Nobuhiro N et al.

Desmoid tumors are classified as borderline malignancies and are characterized by a high rate of local recurrence despite the absence of distant metastasis. Low-dose methotrexate combined with vinblastine, known as the methotrexate and vinblastine (MV) regimen, has been reported as an effective treatment for desmoid-type fibromatosis (DF). At our institution, we adopt a treatment strategy beginning with celecoxib as the first-line therapy, escalating to the MV regimen only in cases showing disease progression. This study evaluates treatment outcomes based on this protocol. At our institution, 10 patients diagnosed with DF between 2003 and 2025 received surgical resection and/or pharmacotherapy. The standard approach involved initiating treatment with oral celecoxib; if no clinical improvement was observed, therapy was escalated to the MV regimen. Treatment response was assessed using Response Evaluation Criteria in Solid Tumors 1.1 criteria. Of the 10 cases, 1 achieved complete response, 5 showed partial response, 2 maintained stable disease, and 2 exhibited progressive disease, yielding a response rate of 60%. Among patients treated with the MV regimen, extended dosing intervals did not lead to tumor progression, and sustained suppression was observed in several cases. No grade 3 or 4 adverse events were reported. Celecoxib and the MV regimen appear to be effective and well-tolerated options for DF. Given its low toxicity and favorable tolerability, celecoxib should be considered the first-line treatment, especially since tumor control was achieved in half of the cases. Although tumor progression occurred in the remaining cases, disease control was subsequently achieved by introducing the MV regimen. These findings support recent trends favoring nonsurgical management and suggest that the celecoxib followed by the MV regimen strategy should be considered a primary therapeutic approach.

PMID 42760667
Read full article →
PubMedFrontiers in physiology2026-09-19

A model to simulate cardio-respiratory responses to fentanyl analgesia after traumatic injury.

Kurian Varghese V, Jin Xin X, Wallqvist Anders A, Reifman Jaques J et al.

Prehospital pain management is challenging and is expected to become even more complex in future large-scale combat operations, where mass-casualty events and evacuation delay may be inevitable. An improved understanding of how analgesic drugs affect the physiological response of trauma patients can enhance treatment efficacy of combat casualties. We previously developed and validated a cardio-respiratory (CR) model for humans that accounts for vital-sign responses to hemorrhagic injuries, resuscitation with six fluid types, airway obstruction, and ketamine analgesia. Here, we extended the model to include the effect of fentanyl on vital signs by integrating existing fentanyl pharmacokinetic-pharmacodynamic models with the neuronal controller of the model. We calibrated and validated the extended model using experimental data from eight studies involving intravenous fentanyl administration (0.71-50.00 μg/kg) to healthy humans and swine with hemorrhagic injury. The model predictions reasonably captured the trend of the experimental data, with root mean square errors (RMSEs) between model predictions and measured data of 0.83 L/min for minute ventilation (MV), 1.20 mmHg for end-tidal carbon dioxide, 0.09 L for tidal volume, and 1.61 mmHg for mean arterial pressure, all of which were within 3-12% of their baseline values. For plasma fentanyl concentration, we obtained RMSEs of 0.79 μg/L in humans and 25.83 μg/L in swine. In simulations, we observed that as hemorrhage increased from 0 to 40% of blood volume, the fentanyl-induced decrease in MV increased from 19 to 34% of its baseline value prior to administration due to reduced fentanyl clearance. Similarly, in simulations of airway obstruction, the fentanyl-induced decrease in MV was 26% of its baseline value after a 100% obstruction compared to only 19% for a no-obstruction condition. Given that most combat casualties receive either fentanyl or ketamine for pain management, the ability to predict and quantify the physiological effects of these drugs will allow us to generate relevant synthetic datasets of diverse battlefield scenarios.

PMID 42761088
Read full article →
PubMedJournal of clinical hypertension (Greenwich, Conn.)2026-09-19

Office Blood Pressure and Arteriolosclerosis in Biopsy-Proven Glomerulonephritis: Association With Renal Function Decline and Clinical Outcomes.

Gigante Antonietta A, Trombacco Alice A, Galanti Giulia G, Pellicano Chiara C et al.

Hypertension is a major determinant of chronic kidney disease progression, yet the relationship between standardized office blood pressure measurements (OBPM), chronic vascular lesions, and prognosis in biopsy-proven glomerulonephritis (GN) remains poorly defined. We investigated the association between OBPM and renal histopathological lesions, focusing on arteriolosclerosis, and assessed their prognostic significance. This retrospective longitudinal study included 66 adults with biopsy-proven GN. All patients underwent standardized OBPM, laboratory evaluation, and renal biopsy. Histopathological assessment included glomerular, vascular, tubular, and interstitial lesions. Patients were followed for 36 months. Mixed-effects models evaluated longitudinal changes in blood pressure, proteinuria, and estimated glomerular filtration rate (eGFR), while logistic regression identified predictors of renal and cardiovascular outcomes. Patients with arteriolosclerosis had significantly higher systolic blood pressure (SBP) than those without (130 vs. 120 mmHg, p = 0.032). SBP > 130 mmHg was associated with arteriolosclerosis (p = 0.004), arterial intimal fibrosis (p = 0.005), crescentic lesions (p = 0.033), and glomerulosclerotic changes (p = 0.048), whereas no associations were observed for diastolic blood pressure (DBP). During follow-up, proteinuria significantly decreased (p < 0.001), whereas SBP remained stable. Arteriolosclerosis was associated with a steeper decline in eGFR over time (interaction β = -4.91 mL/min/1.73 m2 per follow-up interval, p = 0.023) and independently predicted the composite renal and cardiovascular outcome (OR 6.67, 95% CI 1.01-44.31; p = 0.049). In biopsy-proven GN, higher SBP is closely associated with chronic intrarenal vascular lesions, particularly arteriolosclerosis. Arteriolosclerosis independently predicts renal function decline and adverse cardiorenal outcomes, supporting its value as a histopathological marker for risk stratification and individualized blood pressure management.

PMID 42762084
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about MV-130